Big Pharma in Specialist Land: No Proven Advantage Over Small Marketers
Executive Summary
Pfizer's move into the multiple sclerosis market last year, via its agreement to co-promote Serono's version of interferon beta-1a, posed a big challenge for Biogen, the leader in that market. Indeed, the situation is arguably the most visible experiment to date testing whether or not Big Pharmas--which lately have all begun moving into specialist markets--will have significant advantage over the small firms that have until now been the only ones to play there. Biogen's successful response to the challenge suggests that big companies can't dominate small markets just because they're big.
You may also be interested in...
Biogen Defends its Specialist Market
Biogen quickly became the leader in the multiple sclerosis market, growing Avonex into a billion-dollar drug. Now Biogen's dominance is being challenged by Serono and its new partner Pfizer, co-promoting another interferon, Rebif, which came to market with head-to-head data showing it's better. Biogen maintains that Avonex is the best treatment, and is working to support its contention. The biotech is confident that the relationships it has built over time, and strengthened through services, will be hard for newcomers to push aside. The potential for leverage is what attracts Pfizer to this specialist market: it aims to sell Rebif broadly. Its 300 neurology sales reps will carry other products for the co-morbidities MS patients suffer--so the ROI could be good, even if Rebif itself isn't a huge seller. An industry whose pipeline is far richer in niche than GP products will be watching this marketing battle: will Biogen's focus carry the day--or can Pfizer turn a late-entry specialist product into a market leader and in the process, make significant money for itself?
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.